{"id":5506,"date":"2023-05-24T12:04:44","date_gmt":"2023-05-24T12:04:44","guid":{"rendered":"https:\/\/founderlodge.com\/latest-news\/?p=5506"},"modified":"2023-05-24T12:04:46","modified_gmt":"2023-05-24T12:04:46","slug":"quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers","status":"publish","type":"post","link":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/","title":{"rendered":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers."},"content":{"rendered":"\n<figure class=\"wp-block-image size-full is-resized\"><img decoding=\"async\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-282.png\" alt=\"\" class=\"wp-image-5507\" width=\"118\" height=\"118\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-282.png 200w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-282-150x150.png 150w\" sizes=\"(max-width: 118px) 100vw, 118px\" \/><\/figure>\n\n\n\n<p>San Francisco, CA &#8211; <a href=\"https:\/\/www.quantatx.com\/\">Quanta Therapeutics<\/a>, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers, announced today the successful completion of its Series D funding round, raising $50 million. The financing was led by prominent healthcare investment firms <a href=\"https:\/\/vidaventures.com\/\">Vida Ventures LLC<\/a> and <a href=\"https:\/\/www.longitudecapital.com\/\">Longitude Capital<\/a>, along with participation from <a href=\"https:\/\/www.sofinnova.com\/\">Sofinnova Investments<\/a>, <a href=\"https:\/\/www.citadel.com\/what-we-do\/equities\/surveyor-capital\/\">Surveyor Capital<\/a>, Avidity Partners, and <a href=\"https:\/\/www.abbvie.com\/\">AbbVie<\/a>.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"561\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-283-1024x561.png\" alt=\"\" class=\"wp-image-5508\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-283-1024x561.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-283-300x164.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-283-768x421.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-283.png 1335w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Quanta Therapeutics, founded by renowned scientist Dr. <a href=\"https:\/\/www.linkedin.com\/in\/perry-nisen-91115818\">Perry Nisen<\/a>, is pioneering the development of best-in-class allosteric inhibitors to target previously undruggable RAS mutations in challenging-to-treat cancers, including lung, colon, and pancreatic cancer. While existing KRAS inhibitors have made significant strides in targeting the KRAS G12C mutation, these therapies are limited to approximately ten percent of KRAS-driven cancers and are currently approved only for non-small cell lung cancer patients in later lines of therapy.<\/p>\n\n\n\n<p>The company&#8217;s primary focus is on modulating RAS signaling at the cell membrane, aiming to expand the scope of treatable RAS-driven cancers. Leveraging deep biologic insights, novel protein conformation detection technology, and sophisticated medicinal chemistry expertise, Quanta Therapeutics is dedicated to developing next-generation oral small molecules that have the potential to revolutionize KRAS therapy.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"558\" src=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-284-1024x558.png\" alt=\"\" class=\"wp-image-5509\" srcset=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-284-1024x558.png 1024w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-284-300x164.png 300w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-284-768x419.png 768w, https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-284.png 1176w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>&#8220;We are thrilled to have secured this substantial funding in our Series D round, which will propel our efforts in combating RAS-driven cancers,&#8221; said Dr. Perry Nisen, Founder of Quanta Therapeutics. &#8220;This financing enables us to advance our groundbreaking research and expedite the development of novel allosteric inhibitors that can address the unmet needs of patients suffering from a range of RAS-driven cancers.&#8221;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>San Francisco, CA &#8211; Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers, announced today the successful completion of its Series D funding round, raising $50 million. The financing was led by prominent healthcare investment firms Vida Ventures LLC and Longitude Capital, along with participation from Sofinnova Investments, Surveyor [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":5510,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_genesis_hide_title":false,"_genesis_hide_breadcrumbs":false,"_genesis_hide_singular_image":false,"_genesis_hide_footer_widgets":false,"_genesis_custom_body_class":"","_genesis_custom_post_class":"","_genesis_layout":""},"categories":[2],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.2.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News<\/title>\n<meta name=\"description\" content=\"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News\" \/>\n<meta property=\"og:description\" content=\"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Founder Lodge Latest News\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-24T12:04:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-24T12:04:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-285.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1523\" \/>\n\t<meta property=\"og:image:height\" content=\"786\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"ucheezuma\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ucheezuma\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\"},\"author\":{\"name\":\"ucheezuma\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\"},\"headline\":\"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers.\",\"datePublished\":\"2023-05-24T12:04:44+00:00\",\"dateModified\":\"2023-05-24T12:04:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\"},\"wordCount\":268,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"articleSection\":[\"Daily Startup Funding News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\",\"name\":\"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News\",\"isPartOf\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\"},\"datePublished\":\"2023-05-24T12:04:44+00:00\",\"dateModified\":\"2023-05-24T12:04:46+00:00\",\"description\":\"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,\",\"breadcrumb\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/founderlodge.com\/latest-news\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#website\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"name\":\"Founder Lodge Latest News\",\"description\":\"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.\",\"publisher\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#organization\",\"name\":\"Founder Lodge\",\"url\":\"https:\/\/founderlodge.com\/latest-news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Founder Lodge\"},\"image\":{\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3\",\"name\":\"ucheezuma\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g\",\"caption\":\"ucheezuma\"},\"url\":\"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News","description":"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/","og_locale":"en_US","og_type":"article","og_title":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News","og_description":"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,","og_url":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/","og_site_name":"Founder Lodge Latest News","article_published_time":"2023-05-24T12:04:44+00:00","article_modified_time":"2023-05-24T12:04:46+00:00","og_image":[{"width":1523,"height":786,"url":"https:\/\/founderlodge.com\/latest-news\/wp-content\/uploads\/2023\/05\/image-285.png","type":"image\/png"}],"author":"ucheezuma","twitter_card":"summary_large_image","twitter_misc":{"Written by":"ucheezuma","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#article","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/"},"author":{"name":"ucheezuma","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3"},"headline":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers.","datePublished":"2023-05-24T12:04:44+00:00","dateModified":"2023-05-24T12:04:46+00:00","mainEntityOfPage":{"@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/"},"wordCount":268,"commentCount":0,"publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"articleSection":["Daily Startup Funding News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/","url":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/","name":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers. - Founder Lodge Latest News","isPartOf":{"@id":"https:\/\/founderlodge.com\/latest-news\/#website"},"datePublished":"2023-05-24T12:04:44+00:00","dateModified":"2023-05-24T12:04:46+00:00","description":"San Francisco, CA - Quanta Therapeutics, a leading biotechnology research company focused on developing innovative treatments for RAS-driven cancers,","breadcrumb":{"@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/founderlodge.com\/latest-news\/quanta-therapeutics-raises-50-million-in-series-d-funding-round-to-advance-development-of-allosteric-inhibitors-for-ras-driven-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/founderlodge.com\/latest-news\/"},{"@type":"ListItem","position":2,"name":"Quanta Therapeutics Raises $50 Million in Series D Funding Round to Advance Development of Allosteric Inhibitors for RAS-Driven Cancers."}]},{"@type":"WebSite","@id":"https:\/\/founderlodge.com\/latest-news\/#website","url":"https:\/\/founderlodge.com\/latest-news\/","name":"Founder Lodge Latest News","description":"Get the latest updates on funding rounds and investment news for startups and businesses. Stay informed on capital raising trends and who&#039;s raising capital.","publisher":{"@id":"https:\/\/founderlodge.com\/latest-news\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/founderlodge.com\/latest-news\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/founderlodge.com\/latest-news\/#organization","name":"Founder Lodge","url":"https:\/\/founderlodge.com\/latest-news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Founder Lodge"},"image":{"@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/2854d3c2f2bb3f7ff9ae13c649048af3","name":"ucheezuma","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/founderlodge.com\/latest-news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ff09ab70d3a1229d484147623818e0af?s=96&d=mm&r=g","caption":"ucheezuma"},"url":"https:\/\/founderlodge.com\/latest-news\/author\/ucheezuma\/"}]}},"_links":{"self":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/5506"}],"collection":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/comments?post=5506"}],"version-history":[{"count":1,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/5506\/revisions"}],"predecessor-version":[{"id":5511,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/posts\/5506\/revisions\/5511"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media\/5510"}],"wp:attachment":[{"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/media?parent=5506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/categories?post=5506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/founderlodge.com\/latest-news\/wp-json\/wp\/v2\/tags?post=5506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}